APOE3 - R136S mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition

Probably not a substantial claim: may not pass S3 (load-bearing).

Amyloid pathology induces abnormal theta and gamma oscillations, likely due to deficient inhibitory interneuron activity.

“Previous studies have shown that amyloid pathology induces abnormal theta and gamma oscillations, likely due to deficient inhibitory interneuron activity”

• cites [20] sourceDisputed

  The Results section (page unavailable) reports increased theta power and increased interneuron firing in aged EC-Tau mice, but no significant difference in gamma power. The Discussion attributes these changes to tau pathology and suggests increased, not deficient, inhibitory activity. The paper therefore does not support the claimed amyloid-driven mechanism and reports contrary findings for gamma and interneuron activity. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [47] sourceNot checked — no full text of the source
• cites [48] sourcePartly supported

  The Results section reports abnormal gamma oscillations in hAPPJ20 mice, and the Discussion links reduced gamma activity to dysfunction of inhibitory parvalbumin interneurons. Our copy does not report abnormal theta oscillations; a search for “theta” found no supporting passage. The findings are in an amyloid-related mouse model, rather than a direct demonstration that amyloid pathology induces both rhythms. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Marino et al. developed an APOE3 Christchurch-inspired antibody to disrupt human APOE4-HSPG interactions, resulting in reduced tau pathology in the retinas and brains of P301S mice.

“Marino et al. developed an APOE3 Christchurch-inspired antibody to disrupt human APOE4-HSPG interactions, resulting in reduced tau pathology in the retinas and brains of P301S mice62.”

• cites [62] sourcePartly supported

  The Results (Figure 4E–G; page unavailable) report that the Christchurch-mimetic antibody reduced ApoE3-induced tau phosphorylation in P301S mouse retinas. The paper explicitly says that retinal model did not assess brain changes; reduced brain tau phosphorylation was measured separately in APOE4 knock-in mice (Results, Figure 5; page unavailable). Thus the claim incorrectly places both the brain result and the APOE4 result in P301S mice. (LLM, conf=0.93)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The three major APOE variants, APOE2, APOE3, and APOE4, differ from each other at two amino acid positions, 112 and 158, and modulate AD risk; E3 is considered neutral, E4 elevates AD risk, and E2 reduces AD risk.

“The three major APOE variants, APOE2, APOE3, and APOE4, differ from each other at two amino acid positions, 112 and 158, and modulate AD risk. E3 is the most common APOE variant and is considered neutral with regards to AD risk, while E4 alleles elevate AD risk and E2 reduces AD risk12,13.”

• cites [12] sourceNot checked — no full text of the source
• cites [13] sourcePartly supported

  The Introduction (page unavailable) states that APOE4 is associated with increased risk of sporadic Alzheimer’s disease. Our copy does not state that APOE2 reduces risk, that APOE3 is the most common or risk-neutral variant, or that the three variants differ at amino acid positions 112 and 158. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Most AD patients have sporadic late-onset AD, in which the APOE gene contains a predominant risk variant.

“Most AD patients have sporadic late-onset AD (LOAD), in which the apolipoprotein E (APOE) gene contains a predominant risk variant6,7.”

• cites [6] sourcePartly supported

  The ‘ApoE and Neuropathology’ section identifies apoE4 as the major known genetic risk factor for AD in many populations. It does not establish that most AD patients have sporadic late-onset AD or specifically tie that risk-factor statement to late-onset disease. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [7] sourcePartly supported

  The Discussion (page not available in our copy) identifies the APOE ε4 allele as a genetic risk factor for sporadic AD, supporting the risk-variant portion of the claim. It does not say that most AD patients have sporadic late-onset disease or that ε4 is the predominant risk variant. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

APOE is a lipid transporter expressed on astrocytes and microglia and affects numerous microglial functions including neuroinflammation and phagocytosis.

“APOE is a lipid transporter expressed on astrocytes and microglia and has been shown to affect numerous microglial functions including neuroinflammation and phagocytosis8–10.”

• cites [8] sourcePartly supported

  The Results section on APOE expression reports that APOE is predominantly expressed by astrocytes and is also expressed by microglia. The Results and Discussion link APOE4 to changes in microglial immune responses and a pro-inflammatory phenotype. The Discussion mentions phagocytosis as a trigger for a microglial state, but does not show that APOE affects phagocytosis; the searched passages also do not explicitly call APOE a lipid transporter. No page numbers were available in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [9] sourceSupported
• cites [10] sourcePartly supported

  The paper’s Abstract reports that ApoE4 increases inflammatory reactivity in cultured microglia and that ApoE genotype affects microglial activation in mice with tau pathology. The passages do not establish the claim that APOE is a lipid transporter expressed on both astrocytes and microglia, or that it affects microglial phagocytosis. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE4 alone is linked to demyelination, even in the absence of tau pathology.

“Notably, APOE4 alone has also been linked to demyelination, even in the absence of tau pathology45.”

• cites [45] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Gamma frequency modulation is beneficial in models with either amyloid and/or tau pathology.

“Indeed, gamma frequency modulation was found to be beneficial in models with either amyloid and/or tau pathology52”

• cites [52] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Amyloid pathology typically develops early in AD whereas tau pathology occurs later but correlates more accurately with AD progression and cognitive impairment.

“Amyloid pathology typically develops early in AD whereas tau pathology occurs later but correlates more accurately with AD progression and cognitive impairment3–5.”

• cites [3] sourcePartly supported

  In the F-flutametamol section (page unavailable), the paper says amyloid PET retention begins about two decades before symptoms and reports that tau is more closely associated than amyloid with neurodegeneration and cognitive impairment. It describes tau spreading through the cortex in the presence of amyloid, but does not establish that tau pathology itself first occurs later than amyloid pathology. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [4] sourceCould not verify

  The Introduction discusses aminoacyl-tRNA synthetases, and the retrieved WRS signaling and clinical relevance passages discuss tryptophanyl-tRNA synthetase rather than Alzheimer’s disease. Searches for amyloid, tau, AD progression, and cognitive impairment found no passage addressing the claimed timing or correlation of these pathologies. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [5] sourcePartly supported

  The Abstract says Aβ acts upstream of tau in AD pathogenesis, and the In Vivo Evidence for Tau-Dependent Aβ Toxicity section links tau to learning and memory deficits in mouse models. Those passages support the broad sequence and tau’s relevance to cognition, but they do not establish that amyloid pathology typically appears earlier than tau pathology or that tau pathology correlates more accurately with AD progression and cognitive impairment. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

In macrophages, HSPGs modulate inflammation through IFN-β; HSPGs sequester IFN-β, and the degree of proteoglycan sulfation can influence inflammatory responses.

“In macrophages, HSPGs modulate inflammation through interferon-beta (IFN-β); specifically, HSPGs sequester IFN-β, and the degree of proteoglycan sulfation can influence inflammatory responses63.”

• cites [63] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Neurogenesis is elevated in response to hyperexcitability.

“Neurogenesis is known to be elevated in response to hyperexcitability53,54”

• cites [53] sourceCould not verify

  The Results section on GABAA receptor treatment reports increased newborn-cell proliferation after reduced GABA signaling, but does not establish hyperexcitability or show that it elevates neurogenesis. The Discussion addresses GABAergic excitation in newborn-neuron maturation, not neurogenesis as a response to hyperexcitability. Searches for hyperexcitability, seizures, and increased neuronal activity found no passage making the attributed claim; page numbers were unavailable in our copy. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites [54] sourcePartly supported

  The Abstract says electroconvulsive shock markedly increases adult hippocampal neurogenesis, supporting an elevation in one model of hyperexcitation. But “Activation and exhaustion of NSCs” says seizures produce an initial boost in cell proliferation followed by a decline in neurogenesis to a minimum over the following weeks. The unqualified claim omits that time-dependent, contradictory response. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

E3 and E3S/S iPSCs were differentiated into microglia-like cells (iMGLs), confirmed by the expression of microglia markers IBA1 and TMEM119.

“E3 and E3S/S iPSCs were differentiated into microglia-like cells (iMGLs)43 (Fig. 6A), confirmed by the expression of microglia markers, IBA1 and TMEM119 (Fig. 6B).”

• cites [43] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Agonist of EAAT2 is neuroprotective.

“Given that agonist of EAAT2 has been found to be neuroprotective57”

• cites [57] sourcePartly supported

  The paper’s Abstract reports that LDN/OSU-0212320 protected cultured neurons from glutamate-mediated injury via EAAT2 activation. The results section specifies that the compound increased EAAT2 expression through translational activation; it does not establish that the compound is an EAAT2 agonist. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

In mouse models on the risk-enhancing APOE4 background, the R136S mutation protected against tau pathology, neurodegeneration, and neuroinflammation.

“In mouse models on the risk-enhancing APOE4 background, the R136S mutation was found to protect against tau pathology, neurodegeneration, and neuroinflammation14.”

• cites [14] sourceSupported

May combine two claims.

Cgas deletion mitigated tauopathy-induced microglial IFN-I and protected against synapse loss, synaptic plasticity, and cognitive deficits.

“Cgas deletion mitigated tauopathy-induced microglial IFN-I and protected against synapse loss, synaptic plasticity, and cognitive deficits41.”

• cites [41] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

These gangliosides are known to form toxic aggregates commonly associated with neurodegenerative diseases such as FTD and Gaucher's disease.

“These gangliosides are known to form toxic aggregates commonly associated with neurodegenerative diseases, such as frontotemporal dementia (FTD)38 and Gaucher’s disease58.”

• cites [38] sourcePartly supported

  The Results section reports increased ganglioside levels in frontal lobes from patients with GRN-associated FTD, supporting the FTD association attributed to this citation. The paper does not say that gangliosides form toxic aggregates; its Discussion refers instead to possible protein aggregation following gangliosidosis. Gaucher’s disease has a separate citation in the citing sentence and is not assessed here. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [58] sourcePartly supported

  The Discussion says exosomes containing gangliosides may accelerate α-synuclein aggregation in Parkinson’s disease with a GBA mutation. It does not say that gangliosides themselves form toxic aggregates in Gaucher’s disease; the Introduction identifies different lipids, glucosylceramide and glucosylsphingosine, as accumulating in that disease. The FTD example has a separate citation in the citing sentence. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

The cGAS-STING pathway was previously shown to play a role in tau-induced neurodegeneration.

“The cGAS-STING pathway was previously shown to play a role in tau-induced neurodegeneration41.”

• cites [41] sourceSupported

May combine two claims.

APOE4 greatly exacerbates tau-induced neurodegeneration, partially attributed to a critical immune hub involving IFN-driven microglial activation and interaction with cytotoxic T cells.

“Moreover, APOE4 greatly exacerbates tau-induced neurodegeneration, partially attributed to a critical immune hub that involves IFN-driven microglial activation and interaction with cytotoxic T cells60,61.”

• cites [60] sourcePartly supported

  The paper reports that ApoE4 aggravates tau-mediated neurodegeneration and is associated with increased microglial activation (Abstract; Extended Data Figure 9). It does not identify an IFN-driven immune hub or interactions with cytotoxic T cells as the mechanism; instead, it discusses heightened innate immune reactivity and possible effects of activated microglia and astrocytes. The indexed copy provides no page numbers for these passages. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [61] sourcePartly supported

  The Abstract (page not provided) reports prominent atrophy in tauopathy mice expressing either APOE3 or APOE4, with only 'somewhat greater' atrophy in the APOE4 mice; it does not support 'greatly exacerbates' relative to APOE3. The Abstract and 'Interaction of microglia and T cells' section (pages not provided) support the described immune hub involving IFN-activated microglia and cytotoxic T cells. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

AD patients exhibit increased myelin loss.

“AD patients exhibit increased myelin loss”

• cites [43] sourceCould not verify

  The Background and Discussion discuss microglia in Alzheimer’s disease, and the Results examine phagocytosis of beta-amyloid by stem-cell-derived microglia. None reports myelin loss in AD patients; searches for myelin loss and demyelination found no supporting passage in our copy. No page numbers were provided. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [44] sourceCould not verify

  The Introduction discusses cGAS-related autoinflammation, and the Methods describe experiments using cells from healthy donors; neither addresses myelin loss in AD patients. Searches for “myelin loss Alzheimer disease AD patients” and “demyelination Alzheimer's patients” found no passage in our copy supporting the claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

FTD tau pathology leads to network dysfunction similar to that in AD, suggesting converging network dysfunction in AD and primary tauopathies.

“The revelation that frontotemporal dementia (FTD) tau pathology led to similar network dysfunction suggests converging network dysfunction in AD and primary tauopathies49–51”

• cites [49] sourcePartly supported

  The Introduction describes neuronal network dysfunction in AD, and the Discussion reports impaired inhibitory transmission in APP/PS1 mice. The cited paper does not report FTD tau pathology causing similar dysfunction or compare AD with primary tauopathies (searched: FTD tau pathology; primary tauopathies). (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [50] sourcePartly supported

  The Discussion reports network dysfunction in AD and cell-type-specific activity deficits in APP/PS1 mice. It does not address FTD tau pathology or compare its network effects with AD, so it does not support the claimed convergence. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [51] sourcePartly supported

  In “Targets to Improve GABA Inhibitory Interneuron Activity” (page unavailable), the review reports that mutant tau causes grid-cell dysfunction and that tau phosphorylation produces abnormal neural network activity in TauP301L mice. It does not identify these findings as FTD pathology or compare network dysfunction in FTD with AD, so the proposed convergence between AD and primary tauopathies is not established by this source. (LLM, conf=0.81)

  Experimental — accuracy not yet measured

May combine two claims.

Tauopathy increased c-Fos-based brain activity on the E3 background, but this was reversed on the E3S/S background.

“Tauopathy increased c-Fos-based brain activity on the E3 background, but this was reversed on the E3S/S background (Fig. S2B–C).”

Probably not a substantial claim: may not pass S3 (load-bearing).

STRING analysis identified Rbm25 as a central hub among shared splicing-related genes.

“Within these shared genes, STRING analysis identified Rbm25 as a central hub (Fig. S4F).”

Probably not a substantial claim: may not pass S3 (load-bearing).

Another top downregulated gene in astrocytes was Grm5.

“Another top downregulated gene in astrocytes was metabotropic glutamate receptor 5 (Grm5) (Fig. S4K).”

Probably not a substantial claim: may not pass S3 (load-bearing).

Upregulated genes in excitatory neurons were involved in regulation of membrane potential, inorganic ion transmembrane transport, and RNA processing.

“Using gene set enrichment analysis (GSEA), we found that upregulated genes in ENs also were involved in regulation of membrane potential, inorganic ion transmembrane transport, and RNA processing (Pnn, Pnisr) (Fig. S4B).”

May combine two claims.

Microglia in E3/P301S and E3S/S/P301S mice exhibited similar loss of microglial subcluster 1 (MG1) and similar induction of DAM.

“Specifically, microglia in E3/P301S and E3S/S/P301S mice exhibited similar loss of microglial subcluster 1 (MG1) enriched with homeostatic markers (Table S3), and similar induction of DAM shown by subcluster 2 (MG2) (Fig. 4F–H, Table S3).”

May combine two claims.

Tau reduced average gamma power regardless of E3 and E3S/S background, but failed to reduce gamma power in the dentate gyrus on the E3S/S background.

“While tau pathology appeared to reduce average gamma power regardless of E3 and E3S/S background (Fig. 2G), it failed to reduce the gamma power in the DG on E3S/S background (Fig. 2 H,I).”

May combine two claims.

Tau increased soma volume in E3/P301S microglia, while the E3S/S mutation prevented this increase.

“Using IMARIS 3D reconstruction to assess microglial morphology, we found that tau increased soma volume in E3/P301S microglia, while the E3S/S mutation prevented this increase (Fig. 4C–D).”

May combine two claims.

E3S/S iMGLs exhibited increased intracellular tau compared to E3 iMGLs, while media from E3S/S cells contained less extracellular tau.

“E3S/S iMGLs exhibited increased intracellular tau compared to E3 iMGLs, while media from E3S/S cells contained less extracellular tau (Fig. 6C–E).”

May combine two claims.

Similar overlaps and strong correlations in expression patterns were observed in excitatory neurons (R=0.95) and inhibitory neurons (R=0.98).

“Similarly, striking overlaps and strong correlations in expression patterns were observed in excitatory neurons (ENs; R=0.95, Fig. 7H–J, Table S5) and inhibitory neurons (INs; R=0.98, Fig. 7K–L, S6E, Table S5).”

May combine two claims.

Tau-treated E3S/S microglia showed enrichment in transcription-related pathways, while Aβ-treated E3S/S microglia upregulated pathways involved in the extracellular matrix, plasma membrane, and matrisome.

“Tau-treated E3S/S microglia showed enrichment in transcription-related pathways, such as transcriptional regulation, DNA binding, and RNA polymerase II activity, while Aβ-treated E3S/S microglia upregulated pathways involved the extracellular matrix, plasma membrane, and matrisome (Fig. S5D).”

May combine two claims.

IPA confirmed that the top inhibited upstream regulators in E3S/S/P301S microglia included antiviral activators cGAS and IFNA, and top activated upstream regulators included TREX1 and RNASEH2B.

“Ingenuity Pathway Analyses confirmed that the top inhibited upstream regulators in E3S/S/P301S microglia included antiviral activators as cGAS and IFNA, and top activated upstream regulators include those involved in suppressing antiviral response such as TREX1, RNASEH2B (Fig 4K).”

May combine two claims.

The resilient E3S/S allele selectively suppresses tau-induced cGAS-STING-IFN signaling in microglia while maintaining DAM responses.

“Our current findings reveal that the resilient E3S/S allele selectively suppresses tau-induced cGAS-STING-IFN signaling in microglia while maintaining DAM responses”

May combine two claims.

Induction of type-I interferon genes by tau was blunted in E3S/S/P301S microglia whereas E3/P301S counterparts demonstrated a robust type I interferon response to tau.

“Visualizing all genotypes together showed that induction of type-I interferon genes by tau was blunted in E3S/S/P301S microglia whereas E3/P301S counterparts demonstrated a robust type I interferon response to tau (Fig 4J).”

May combine two claims.

Fewer DEGs were observed in interneurons, and the top pathways were also associated with RNA processing.

“Although fewer DEGs were observed in interneurons, the top pathways were also associated with RNA processing (Fig. 3B, S4D).”

May combine two claims.

Immunostaining with anti-MBP revealed higher levels of myelin in the hippocampus of E3S/S mice, and a strong protective effect of E3S/S against tau-induced myelin loss.

“immunostaining with anti-MBP revealed higher levels of myelin in the hippocampus of E3S/S mice, and a strong protective effect of E3S/S against tau-induced myelin loss (Fig. 3J–K),”

May combine two claims.

Tau treatment significantly increased levels of pSTING and pTBK1 in E3 iMGLs, but this activation was abolished in E3S/S iMGLs.

“Immunocytochemistry showed that tau treatment significantly increased levels pSTING and pTBK1 in E3 iMGLs, but this activation was abolished in E3S/S iMGLs, indicating that R136S suppresses tau-induced activation of the cGAS-STING-IFN pathway (Fig. 6G–J).”

Classified as probably not a substantial claim.

Sanger sequencing confirmed the accuracy of the replacement.

“Sanger sequencing was performed to confirm the accuracy of the replacement (Fig. S1 B, C).”

May combine two claims.

The R136S mutation enhances tau uptake and processing while dampening downstream cGAS-STING-IFN activation in both mouse and human microglia.

“In summary, the R136S mutation enhances tau uptake and processing while dampening downstream cGAS-STING-IFN activation in both mouse and human microglia.”

Classified as probably not a substantial claim. May combine two claims.

The R136S mutation may confer additional cGAS-independent protective effects, or earlier intervention is required, or both.

“indicating that the R136S mutation may confer additional cGAS-independent protective effects, or that earlier intervention is required, or both”

Probably not a substantial claim: may not pass S3 (load-bearing).

EAAT2 expression diminishes with age.

“Its expression diminishes with age55”

• cites [55] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

In postmortem brains of patients with sporadic AD, EAAT2 expression correlates with signs of neuronal death.

“in postmortem brains of patients with sporadic AD correlates with signs of neuronal death56”

• cites [56] sourceNot checked — no full text of the source

May combine two claims.

This provides a protective mechanism that mitigates tau pathology and preserves cognitive and synaptic functions by balancing immune activation and resilience pathways.

“providing a protective mechanism that mitigates tau pathology and preserves cognitive and synaptic functions by balancing immune activation and resilience pathways”

• AssumptionRests on an assumption: Interferon pathways are particularly damaging, especially in the presence of tau pathology.

Probably not a substantial claim: may not pass S3 (load-bearing).

The downregulation of c-FOS activity by the R136S mutation could help explain the reduction in neurogenesis.

“The downregulation of c-FOS activity by the R136S mutation could help explain the reduction in neurogenesis.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The R136S mutation enhances microglial response around amyloid plaques on E3 background.

“Previous findings showed that R136S mutation enhances microglial response around amyloid plaques on E3 background15”

• cites [15] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

205,400 nuclei were analyzed after stringent quality control, with all major cell types similarly represented across genotypes.

“A total of 205,400 nuclei were analyzed after stringent quality control, with all major cell types similarly represented across genotypes (Fig. S7).”

Probably not a substantial claim: may not pass S3 (load-bearing).

Mouse lines without nonspecific integration for both E3 and E3S/S were expanded for subsequent experiments.

“The mouse lines without nonspecific integration for both E3 and E3S/S were expanded for subsequent experiments.”

Probably not a substantial claim: may not pass S3 (load-bearing).

88,605 nuclei passed stringent quality control in the snRNA-seq of hippocampi.

“88,605 nuclei passed the stringent quality control (QC) (Fig. S3).”

May combine two claims.

cGAS inhibition reduced tau spread, and treatment initiated after disease onset recapitulates some key aspects of the R136S mutation-mediated resilience to tau toxicity, including transcriptomic changes in neurons and microglia and preservation of synaptic integrity.

“In summary, cGAS inhibition reduced tau spread, and treatment initiated after disease onset recapitulates some key aspects of the R136S mutation-mediated resilience to tau toxicity, including transcriptomic changes in neurons and microglia and preservation of synaptic integrity.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Experimenters performing imaging and quantification were blinded.

“Experimenters performing imaging and quantification were blinded.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Potential doublet cells were predicted using DoubletFinder for each sample separately, with high-confidence doublets removed.

“Potential doublet cells were predicted using DoubletFinder for each sample separately, with high-confidence doublets removed.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Mixed model analysis was used to account for multiple cells in each image and multiple hippocampal sections per animal.

“We used mixed model analysis to account for multiple cells in each image and multiple hippocampal sections/animal.”

Probably not a substantial claim: may not pass S3 (load-bearing).

To control for multiple testing, the Benjamini-Hochberg approach was used to constrain the FDR.

“To control for multiple testing, we used the Benjamini–Hochberg approach to constrain the FDR.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Genes expressed in no more than three cells, cells with unique gene counts over 4,000 or less than 300, cells with UMI counts over 20,000, and cells with a high fraction of mitochondrial reads (>5%) were removed.

“We further removed genes expressed in no more than three cells, cells with unique gene counts over 4,000 or less than 300, cells with UMI counts over 20,000 and cells with a high fraction of mitochondrial reads (>5%).”